[NMusers] Advanced Level Workshop on Pharmacokinetic - Pharmacodynamic Data Analysis

From: Andre Keller <Andre.Keller_at_certara.com>
Date: Mon, 1 Dec 2014 13:11:20 +0000

Dear Members,

You are invited to join Drs. Daniel Weiner and Johan Gabrielsson for the 16=
th Advanced Level Workshop on Pharmacokinetic-Pharmacodynamic Data Analysis=
 in San Diego, CA. Secure your place by registering early and receive a 20%=
 discount! (expires December 15th)

Interested in a custom on-site training course? Follow the link to view the=
 benefits of on-site training and to request a proposal: http://info.certar=

16th Advanced Level Workshop on Pharmacokinetic - Pharmacodynamic Data Anal=
February 17-20, 2015
San Diego, CA
Register Here: https://www.certara.com/training/classes/72
Learn to apply advanced approaches for conducting PK/PD analysis. This cour=
se aims to give the course participants confidence and encouragement to hav=
e a go at PK/PD and to practice PK/PD data analysis on real life case studi=
es from discovery, preclinical and development. The program is comprised o=
f lectures and group exercises with discussion, combined with hands-on PK/P=
D data analysis sessions.

Who should attend?
Scientists with at least five years of experience in PK/PD modeling. Qualif=
ied graduate students.

Topics include:
Dose-response-time analysis, advanced principles of turnover modeling inclu=
ding modeling
tolerance and rebound, approaches to TMDD modeling, approaches to optimizin=
g sampling collection times, modeling PD effects for combination drug treat=
ments, pattern recognition, and translational aspects of PK/PD modeling.

Course includes:

  * Complimentary copy of Pharmacokinetic & Pharmacodynamic Data Analysis=
 [with CDROM]
by Johan Gabrielsson and Dan Weiner.
  * Lectures, group exercises with discussion, and hands-on PK/PD data an=
alysis including
population PK/PD modeling using Phoenix WinNonlin and NLME.
  * Discussions and exercises will enable participants to master state-of=
-the-art approaches to real-life problems.

Daniel Weiner Ph.D.
Dr. Weiner has extensive drug development experience and has served as an e=
xpert consultant
to the U.S. Food and Drug Administration (FDA) on pharmacokinetic modeling =
and bioequivalence assessment. Prior to his previous tenure with Pharsight =
as a Senior Vice President, Dr. Weiner held several management positions in=
cluding Head, Biostatistics, Merrell Dow Pharmaceuticals; Vice President, S=
tatistical Consultants, Inc.; Vice President, Syntex Development Research; =
Senior Vice President and Principal Scientist, Quintiles, and most recently=
, Senior Vice President and Global Head of Clinical Development at IVAX Res=

Johan Gabrielsson Ph.D.
Johan Gabrielsson has been Senior Principal Scientist at AstraZeneca R&D M=
├Âlndal. His responsibilities included kinetic/dynamic related project =
tasks in the CV & GI & CNS & Cancer & Biologics areas. He is a co-author of=
 the textbook 'Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts =
and Applications' 4th ed. (2006). He is professor of Integrative Pharmacolo=
gy at the Swedish Agricultural University in Uppsala, Sweden. He is also ac=
ademically affiliated with Dept. of Pharmaceutics, Univ. Tennessee and Univ=
ersity of Manchester.

He has published extensively in the field of pharmacokinetic-pharmacodynami=
c modelling and reasoning, and has run numerous courses internally and exte=
rnally in the area of biological data analysis since 1985 in Europe, the US=
 and Asia (>4000 participants) at both the undergraduate and graduate level=
. His research focuses on modelling different aspects of endogenous turnove=
r, such as functional tolerance and rebound phenomena, physiological limits=
 and target-mediated drug disposition in collaboration with Professor LA Pe=
letier, Leiden University. He has been external examiner on several PhD The=
ses abroad.

Kind regards,
Andre Keller
5520 Dillard Dr., Suite 260
Cary, NC 27518
Tel +1-919-852-4611
www.certara.com<http://www.certara.com/> NOTICE: The information co=
ntained in this electronic mail message is intended only for the personal a=
nd confidential use of the designated recipient(s) named above. This m=
essage may be an attorney-client communication, may be protected by th=
e work product doctrine, and may be subject to a protective order. As such,=
 this message is privileged and confidential. If the reader of this me=
ssage is not the intended recipient or an agent responsible for delivering =
it to the intended recipient, you are hereby notified that you have re=
ceived this message in error and that any review, dissemination, distr=
ibution, or copying of this message is strictly prohibited. If you have rec=
eived this communication in error, please notify us immediately by tel=
ephone and e-mail and destroy any and all copies of this message in yo=
ur possession (whether hard copies or electronically stored copies). Thank =
you. buSp9xeMeKEbrUze

Received on Mon Dec 01 2014 - 08:11:20 EST

This archive was generated by hypermail 2.3.0 : Fri Sep 27 2019 - 16:42:20 EDT